ESR1 and breast cancer: These authors maintained that one-half of the patients with ER+ BC fail to respond favorably to antiestrogen treatment with tamoxifen due to the altered tamoxifen metabolism or bioavailability following the intratumoral alteration in expression of genes coding for xenobiotic-metabolizing enzymes.